Business
Syndax to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 7, 2020
WALTHAM, Mass., April 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage
About this update from Syndax Pharmaceuticals, Inc.
[{"type":"text","content":"WALTHAM, Mass., April 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (\"Syndax,\" the \"Company\" or \"we\") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2020 financial results on Thursday, May 7, after the close of the U.S. financial markets.\nIn connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, May 7, to discuss the Company's financial results and provide a general business update.\nThe live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website at www.syndax.com. Alternatively, the conference call may be accessed through the following:\nConference ID: 5579109Domestic Dial-in Number: (855) 251-6663International Dial-in Number: (281) 542-4259Live webcast: https://edge.media-server.com/mmc/p/pnyq8m58\nFor those unable to participate in the conference call or webcast, a replay will be available for 30 days on the Investors section of the Company's website, www.syndax.com.\nAbout Syndax Pharmaceuticals, Inc. \nSyndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's lead product candidate, entinostat, a once-weekly, oral, small molecule, class I HDAC inhibitor, is being tested in a Phase 3 combination trial with exemestane for treatment of advanced HR+, HER2- breast cancer and has been evaluated in combination with several approved PD-1/PD-(L)1 antagonists. The Company's pipeline also includes axatilimab (SNDX-6352), a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. \nSyndax's Cautionary Note on Forward-Looking Statements\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as \"may,\" \"will,\" \"expect,\" \"plan,\" \"anticipate,\" \"estimate,\" \"intend,\" \"believe\" and similar expressions (as well as other words or expressions referencing futu...